About Altor

Altor BioScience is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer and viral infections, based on its engineered cytokine technology platforms.

Our History

Altor was formed in 2002 by Dr. Hing C. Wong as a spin-off from Sunol Molecular Corporation (“Sunol”), and is backed by leading venture capital funds, including Sanderling Ventures and TVM Capital. The Company has two proprietary technology platforms: the STAR™ platform and the IL-15 Superagonist platform.